AB0911 EFFICACY OF LOW-DOSE IL-2 IN PATIENTS WITH MYOSITIS

Abstract

BackgroundIdiopathic inflammatory myopathies (IIMs) are a group of rare and heterogeneous muscle inflammatory diseases characterized by disturbances of regulatory T(Treg) cells. Interleukin (IL)-2 has been rediscovered as a pivotal cell population in the control of autoimmunity, which effectively relieves idiopathic inflammatory myopathies(IIMs) such as polymyositis(PM) and dermatomyositis (DM).ObjectivesThis study aimed to systematically evaluate the efficacy of low-dose IL-2 therapy in PM, DM, and IIMs.MethodsSystematic searches of PubMed, EMBASE, Web of Science, the Cochrane Library and Medline, CNKI, CBM, and Technology Journal Database were performed. Original case reports, case series, observational studies, and clinical trials reporting the changes in the numbers of lymphocyte subsets on PM, DM, and IIMs patients treated with IL-2 were included. A random-effects meta-analysis was performed to calculate the pooled efficacy. Inconsistency was evaluated by using the I2, and Egger tests were used for the evaluation of potential publication bias (STATA v.12.0)ResultsA total of 5 studies comprising 401 patients were identified(Table 1).The CDASI scores were significantly decreased after IL-2 treatment[SMD=-1.146, 95%CI (-1.591,-0.700), P<0.001].Besides, the number of Tregs cells was significantly increased[SMD=-1.146, 95%CI (-1.591,-0.700), P=0.007], and the subgroup analysis was performed based on the dose of IL-2(Figure 1).ConclusionLow-dose IL-2 was promising in the treatment of DM, PM, and IMMs, which could promote the proliferation and functional recovery of Tregs.Table 1.Available evidence including patients with DM, PM, and IIMs treated with low-dose IL-2.Study.Year.Patients(include inanalysis)Gender(female %)Types of diseaseDosageCDASITregsYunzhi2022.13(13)NAIIMs1 million IU every other daybefore:12±7.04after:3±4.07NAMin Feng.2019.35(35)NADM0.5 million IU per day for 5 daysNAbefore:8.1±7.59after:20.71±14.47M. T. Qiu.2020.320(320)NAPM/DMNAbefore:7.14±5.72after:10±7.14before:25.71±22.85after:31.43±25.72M.Miao.2020.15(15)NAIIMs1 million IU every other daybefore:7±5.19after:2±2.96before:8.18±4.27after:15.2±2.69Miao Miao.2021.18(18)NAIIMs1 million IU every other daybefore:7±6.30after:2±5.19before:52.01±8.21after:84.31±20.25Figure 1.The efficacy of low-dose IL-2 therapy in PM, DM and IIMs treatment.(A) CDASI scores.(B) the numbers of Tregs cells.AcknowledgementsThis work was supported by the National Natural Science Foundation of China (No. 82001740).Disclosure of InterestsNone Declared.